Investment Rating - The report maintains a "Buy" rating for the company [5]. Core Insights - The company has entered into a strategic cooperation framework agreement with L Catterton, aiming for global market expansion and optimization of capital structure [1][2]. - The partnership will leverage L Catterton's extensive investment experience in the consumer goods sector to enhance the company's high-end beauty brand positioning and facilitate overseas retail channel expansion [2]. - The company has shown strong sales performance, with a 32% year-on-year increase in sales across major platforms for the period from January to November 2025, indicating robust growth in both makeup and skincare categories [3]. Financial Projections - The company forecasts revenue growth from 2,886 million RMB in 2023 to 8,812 million RMB in 2027, with a compound annual growth rate (CAGR) of approximately 29.9% [4][10]. - Net profit is projected to increase from 662 million RMB in 2023 to 2,041 million RMB in 2027, reflecting a strong growth trajectory [4][10]. - Earnings per share (EPS) are expected to rise from 1.35 RMB in 2023 to 4.16 RMB in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 59 to 19 over the same period [4][10]. Profitability and Valuation Metrics - The company maintains a high gross margin, projected at around 84% for the next few years, indicating strong pricing power and cost management [12]. - Return on equity (ROE) is expected to remain robust, with estimates of 42.8% in 2023 and stabilizing around 33.4% by 2027 [12]. - The valuation metrics suggest a decreasing trend in P/E and P/B ratios, indicating potential for investment attractiveness as earnings grow [13].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report highlights that the reduction in shareholding by major shareholders has been completed, which is expected to contribute to the creation of a high-end luxury beauty ecosystem [5] - The company has signed a strategic cooperation framework agreement with L Catterton Asia Advisors to assist in global market expansion, acquisitions, and strategic investments [8] - The company's strong sales performance in both online and offline channels supports the positive outlook for its future profitability [8] Financial Performance and Forecast - Revenue projections for the company are as follows: - 2023: 2,885.96 million RMB - 2024: 3,884.69 million RMB (growth of 34.61%) - 2025: 5,153.06 million RMB (growth of 32.65%) - 2026: 6,608.46 million RMB (growth of 28.24%) - 2027: 8,340.36 million RMB (growth of 26.21%) [7] - Net profit forecasts are: - 2023: 661.9 million RMB - 2024: 880.6 million RMB (growth of 33.0%) - 2025: 1,212.7 million RMB (growth of 37.7%) - 2026: 1,580.4 million RMB (growth of 30.3%) - 2027: 2,030.8 million RMB (growth of 28.5%) [7] - Earnings per share (EPS) estimates are: - 2023: 3.31 RMB - 2024: 2.18 RMB - 2025: 2.47 RMB - 2026: 3.22 RMB - 2027: 4.14 RMB [7] Strategic Developments - The company plans to utilize the proceeds from the share reduction for investments in the beauty-related industry and personal improvements [8] - The collaboration with L Catterton aims to leverage their global investment network to enhance the company's brand presence in high-end retail channels [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [6] Core Insights - The company achieved a record high in overall package volume in 2025, reaching 30.13 billion packages, a year-on-year increase of 22.2% [2] - The Southeast Asian market showed strong performance with a package volume of 7.66 billion in 2025, up 67.8% year-on-year, capturing a market share of 32.8% [2] - New markets, including Saudi Arabia, UAE, Mexico, Brazil, and Egypt, also demonstrated significant growth, with a package volume of 400 million in 2025, a 43.6% increase year-on-year [2] Summary by Relevant Sections Overall Package Volume - In Q4 2025, the company achieved a total package volume of 8.46 billion, a 14.5% increase year-on-year, with an average daily volume of 92 million packages [1] - The total package volume for 2025 was 30.13 billion, with an average daily volume of 82.5 million packages, reflecting a 22.6% year-on-year growth [2] Southeast Asia Market - In Q4 2025, the company recorded a package volume of 2.44 billion in Southeast Asia, a remarkable 73.6% increase year-on-year, with an average daily volume of 26.5 million packages [1] - The company maintained its leading market share in Southeast Asia for six consecutive years, with a 5.4 percentage point increase from the previous year [2] New Markets - The new markets achieved a package volume of 130 million in Q4 2025, a 79.7% increase year-on-year, with an average daily volume of 1.45 million packages [1] - The company is actively expanding its presence in new markets, leveraging partnerships with e-commerce platforms like TikTok and Mercado Libre [1] Financial Forecasts - The adjusted net profit for 2025-2027 is projected to be $400 million, $710 million, and $990 million, respectively, with corresponding P/E ratios of 33.1x, 18.8x, and 13.5x [10] - Revenue is expected to grow from $10.26 billion in 2024 to $17.39 billion in 2027, reflecting a compound annual growth rate of approximately 16% [12]

Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - Lin Qingxuan, founded in 2003, is a leading high-end domestic skincare brand in China, known for its "oil-based skincare" concept and camellia oil facial essence, focusing on anti-wrinkle and firming skincare products [6][8] - The company has experienced rapid growth, with revenue reaching 1.05 billion yuan in the first half of 2025, a year-on-year increase of 98%, and a net profit margin of 17.3% [6][14] - The market for oil-based skincare is expanding, with a projected market size of 11 billion yuan by 2025, driven by consumer awareness and the rise of domestic brands [6][51] Company Overview - Lin Qingxuan is recognized as a pioneer in the "oil-based skincare" market, with its camellia oil essence being a flagship product that has sold over 45 million bottles since its launch [6][19] - The company operates a multi-channel sales strategy, with 554 physical stores and a significant online presence, particularly on platforms like Douyin, where it holds a 72% market share in its category [6][30][66] - The founder, Sun Laichun, holds a significant stake in the company, which enhances stability and strategic direction [11] Financial Performance - Revenue has grown from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with a compound annual growth rate (CAGR) of 32.42% [14][15] - The gross profit margin for the camellia oil essence has increased from 33% in 2022 to 48% in the first half of 2025, contributing to overall profitability [19][24] Market Dynamics - The "oil-based skincare" market is characterized by a shift towards high-end products, with a significant portion of the market now held by domestic brands [51][53] - Lin Qingxuan leads the market with a 12% share in facial essence sales, outperforming competitors on major e-commerce platforms [55][57] - The demand for oil-based skincare products is driven by a growing understanding of skin barrier science and the need for lipid-based protection [51][64] Product Strategy - The product lineup includes 230 SKUs, with the camellia oil essence accounting for 46% of revenue and 48% of gross profit [19][24] - The company emphasizes the use of natural ingredients and has positioned itself as a high-end brand through effective marketing and product differentiation [6][64] Sales Channels - The company has successfully integrated online and offline sales channels, with online sales accounting for 65% of total revenue in the first half of 2025 [30][66] - Douyin is identified as the primary sales channel for the company, reflecting the effectiveness of live-streaming and visual marketing strategies [66]

Investment Rating - The report does not provide a specific investment rating for the company [1]. Core Insights - The company, Zhipu AI, is a leading independent general large model developer in China, established in 2019, and has developed a unique General Language Model (GLM) framework that excels in long text understanding and logical reasoning [6][12]. - Zhipu AI's flagship products, GLM-4.5 and GLM-4.7, have achieved top rankings in international benchmark tests and have gained significant recognition in the global developer community [6][14]. - The company has a strong market position, ranking first among independent general large model developers in China with a market share of 6.6% as of 2024 [6][15]. - Zhipu AI plans to go public on the Hong Kong Stock Exchange on January 8, 2026, with an IPO price of HKD 116.20 per share, aiming to raise approximately HKD 4.3 billion [6][15]. Summary by Sections 1. Company Overview - Zhipu AI is built on technology from Tsinghua University and aims to compete with OpenAI, focusing on a self-regressive fill-in-the-blank GLM framework [12][16]. - The company has released several significant models, including the GLM-130B, which marked its entry into the mainstream large language model market [12][16]. 2. Business Model and Operations - The business model is centered around Model as a Service (MaaS), offering both localized and cloud deployment options [21][24]. - Localized deployment accounts for a significant portion of revenue, with high margins, while cloud deployment is rapidly growing and aims to capture a larger market share [24][25]. 3. Historical Financial Analysis - Revenue has shown rapid growth, with projections indicating revenues of CNY 785 million in 2025 and CNY 1.55 billion in 2026, reflecting a compound annual growth rate of over 130% from 2022 to 2024 [1][30]. - The company has been operating at a loss due to substantial R&D investments, with cumulative R&D expenses exceeding CNY 4.4 billion from 2022 to 2024 [6][30]. 4. Core Competitiveness - Zhipu AI's competitive edge lies in its fully self-developed technology system, leading model performance, and a robust open-source ecosystem [38][39]. - The GLM series models have demonstrated significant advantages in various applications, including multi-modal understanding and generation [39][40]. 5. Profitability Forecast and Investment Suggestions - The company is expected to achieve revenues of CNY 7.9 billion in 2025, CNY 15.5 billion in 2026, and CNY 32.2 billion in 2027, with a gradual shift towards cloud-driven revenue [6][7]. - The overall gross margin is projected to reach 50% by 2025, with improvements in cloud margins as the business scales [6][7].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [2]. Core Insights - The company is positioned to benefit from the accelerating domestic semiconductor equipment replacement and improved order visibility driven by advanced packaging technology [1]. - The company has a comprehensive equipment matrix in advanced packaging, with a leading market share in TCB (Thermal Compression Bonding) and has upgraded its HB (Hybrid Bonding) equipment for mass production [8]. - The company is expected to see significant revenue growth from 2025 to 2027, with projected revenues of HKD 141.14 billion, HKD 165.73 billion, and HKD 189.05 billion, respectively, reflecting year-on-year growth rates of 6.69%, 17.42%, and 14.07% [8]. Summary by Sections 1. Market Performance - The company has experienced a significant market performance shift, with a 44% increase compared to the previous year, while the semiconductor index has shown varied performance [4]. 2. Profit Forecast - The company’s revenue is projected to decline by 24.10% in 2023, followed by a gradual recovery with expected growth rates of 6.69%, 17.42%, and 14.07% from 2025 to 2027 [7]. - The net profit is forecasted to recover from a low of HKD 345 million in 2024 to HKD 1.715 billion by 2027, indicating a strong rebound in profitability [7]. 3. Valuation Recovery - The company is expected to benefit from the long-term trend of advanced packaging, with a clear growth logic supported by order recovery and improved profit structure [8]. - The company’s TCB market share is projected to reach 35%-40% by 2027, with a total potential market exceeding USD 1 billion [66]. 4. Advanced Packaging Growth - The advanced packaging market is anticipated to surpass traditional packaging by 2025, driven by the increasing demand for AI and high-performance computing [36]. - The global advanced packaging market is expected to grow at a CAGR of approximately 10% until 2023, with significant contributions from government policies and diverse downstream demand [37]. 5. Geopolitical and Domestic Market Dynamics - The company is expected to gain market share in China due to the acceleration of domestic substitution and geopolitical factors, with a focus on local supply chain control [8]. - The company has established a strong local presence in China, with a significant portion of its revenue derived from the region, indicating a strategic advantage in the domestic market [35].

Investment Rating - The report suggests a positive outlook for the company, indicating that it is significantly undervalued with a market capitalization of only HKD 2.7 billion, and recommends active attention to the stock [8]. Core Insights - The company has regained global rights for IMM2510 and IMM27M, allowing it to accelerate overseas clinical development [2][8]. - Clinical data for IMM2510 shows promising results, with an objective response rate (ORR) of 35.3% and a progression-free survival (PFS) of 9.4 months, outperforming similar products [3]. - The differentiated advantages of IMM2510 include its ability to activate antibody-dependent cellular cytotoxicity (ADCC) and a broader VEGF blocking mechanism, which may lead to superior efficacy compared to competitors [4][8]. - The safety profile of IMM2510 is manageable, with common grade 3 treatment-related adverse events reported at 8.7% [5][6]. - The company has a rich pipeline with significant product potential, including the CD47CD20 bispecific antibody (IMM0306) and CD47 fusion protein (IMM01), both showing promising clinical efficacy [7][8]. Summary by Sections - **Regained Rights**: The company has terminated its agreement with Axion, regaining control over the global development and commercialization rights for IMM2510 and IMM27M, which is expected to enhance the pace of clinical research [1][2]. - **Clinical Data**: The clinical efficacy of IMM2510 is highlighted by its ORR of 35.3% and PFS of 9.4 months, indicating strong performance compared to similar therapies [3]. - **Differentiation**: IMM2510's unique design allows for enhanced immune response and broader action against various VEGF receptors, positioning it favorably in a competitive market [4]. - **Safety Profile**: The safety of IMM2510 is considered acceptable, with manageable adverse events reported during trials [5][6]. - **Pipeline Potential**: The company’s pipeline includes several promising candidates, with ongoing trials indicating strong potential for future growth in various therapeutic areas [7][8].

市公司 不断运输 2026 年 01 月 07 日 第速递-W 东南亚及新市场业务量高增，上调盈利预测 报告原因：有信息公布需要点评 撸持(维持) | 市场数据: | 2026年01月06日 | | --- | --- | | 收盘价（港币） | 11.20 | | 恒生中国企业指数 | 9244.24 | | 52 周最高/最低 (港币) | 11.34/4.53 | | H 股市值 (亿港币) | 1.005.49 | | 流通 H 股 (百万股) | 8.897.93 | | 汇率（港币/人民币） | 0.9014 | 一年内股价与基准指数对比走势: 130% 资料来源：Bloomberg 相关研究 《极兔速递-W (01519) 点评: 东南亚维持 高景气,新市场打开新增长曲线》 2025/10/15 申万宏源研究微信服务号 投资要点: 财务数据及盈利预测 | 2023 | | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万美元) | 8849 | 10259 | 12406 | 15573 ...

上 市 公 司 交通运输 ——东南亚及新市场业务量高增，上调盈利预测 报告原因：有信息公布需要点评 增持（维持） | 市场数据： | 2026 年 01 月 06 日 | | --- | --- | | 收盘价（港币） | 11.20 | | 恒生中国企业指数 | 9244.24 | | 52 周最高/最低（港币） | 11.34/4.53 | | H 股市值（亿港币） | 1,005.49 | | 流通 H 股（百万股） | 8,897.93 | | 汇率（港币/人民币） | 0.9014 | 一年内股价与基准指数对比走势： -20% 30% 80% 130% HSCEI 极兔速递-W 资料来源：Bloomberg 相关研究 《极兔速递-W（01519）点评：东南亚维持 高 景 气 ， 新 市 场 打 开 新 增 长 曲 线 》 2025/10/15 证券分析师 2026 年 01 月 07 日 极兔速递-W (01519) 闫海 A0230519010004 yanhai@swsresearch.com 研究支持 王易 A0230525050001 wangyi@swsresearch.com 范晨轩 A ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 18.63 [1][10]. Core Views - The company has issued a positive profit forecast, expecting a net profit of at least RMB 2.9 billion for 2025, representing a year-on-year growth of over 128%. This growth is primarily driven by increased sales of electric two-wheelers and product structure optimization [6][10]. - The company is positioned as a leader in the two-wheeler industry, leveraging its systematic advantages in product strength and distribution channels to consolidate its market position. It aims to expand into the mid-to-high-end market and overseas markets to unlock long-term growth potential [6][10]. - The company anticipates achieving high-quality growth in its two-wheeler business in 2025, with expected sales exceeding 16.2 million units, including over 7.4 million units in the second half of 2025, reflecting a year-on-year growth of over 11% [7]. - The company is focusing on the mid-to-high-end market with brands like "Crown" and "Modern," building differentiated competitive barriers. It is also increasing its self-supply ratio in battery production, which will enhance profitability [8]. - The company is benefiting from policy-driven replacement demand in Southeast Asian markets, with local production and policy alignment expected to boost its market share as electric motorcycles replace fuel-powered ones [9]. Financial Projections - The company’s revenue is projected to reach RMB 37.19 billion in 2025, with a year-on-year growth of 31.71%. The net profit attributable to the parent company is expected to be RMB 2.94 billion, reflecting a year-on-year increase of 131.26% [5][10]. - The report forecasts an EPS of RMB 0.99 for 2025, with a projected PE ratio of 10.35 times [5][10]. - The company’s return on equity (ROE) is expected to be 34.77% in 2025, increasing to 39.36% in 2026 [5][10].